Treatment of Refractory and Relapsed Childhood Acute Myelogenous Leukemia with High-Dose Cytosine Arabinoside and Mitoxantrone (HAM): Results of the AML Relapse Study BFM-85

[1]  J. Ritter,et al.  Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in study AML-BFM-83 as compared with study AML-BFM-78. AML-BFM Study Group. , 1990, Blood.

[2]  J. Ritter,et al.  Improved treatment results in the myelocytic subtypes FAB M1-M4 but not in FAB M5 after intensification of induction therapy: results of the German childhood AML studies BFM-78 and BFM-83. , 1990, Haematology and blood transfusion.

[3]  W. Hiddemann,et al.  MITOZANTRONE AND HIGH-DOSE CYTARABINE IN REFRACTORY ADULT ACUTE MYELOID LEUKAEMIA , 1985, The Lancet.

[4]  H. Lazarus,et al.  High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Marcus,et al.  MITOZANTRONE AND HIGH-DOSE CYTARABINE IN ADULT ACUTE MYELOID LEUKAEMIA , 1985, The Lancet.

[6]  J. Glick,et al.  High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute nonlymphocytic leukemia. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  C. Spurr,et al.  Treatment of poor risk acute leukemia with sequential high-dose ARA-C and asparaginase. , 1984, Blood.

[8]  H. Lazarus,et al.  High-dose cytosine arabinoside therapy for refractory leukemia. , 1983, Blood.

[9]  R. Willemze,et al.  High dose cytosine arabinoside in the management of refractory acute leukaemia. , 2009, Scandinavian journal of haematology.

[10]  N. Nissen,et al.  Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. , 1982, Blood.

[11]  Oldham Pd.  Relative merits of different ways of reading tuberculosis , 1952 .